JP2020532987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532987A5 JP2020532987A5 JP2020513604A JP2020513604A JP2020532987A5 JP 2020532987 A5 JP2020532987 A5 JP 2020532987A5 JP 2020513604 A JP2020513604 A JP 2020513604A JP 2020513604 A JP2020513604 A JP 2020513604A JP 2020532987 A5 JP2020532987 A5 JP 2020532987A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- transgene
- sequence
- ligand
- inducible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700019146 Transgenes Proteins 0.000 claims 17
- 239000003446 ligand Substances 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 230000001939 inductive effect Effects 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 101710204410 Scaffold protein Proteins 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108091005703 transmembrane proteins Proteins 0.000 claims 2
- 102000035160 transmembrane proteins Human genes 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 claims 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 claims 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076622A JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556310P | 2017-09-08 | 2017-09-08 | |
| US62/556,310 | 2017-09-08 | ||
| PCT/US2018/050288 WO2019051424A2 (en) | 2017-09-08 | 2018-09-10 | COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076622A Division JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532987A JP2020532987A (ja) | 2020-11-19 |
| JP2020532987A5 true JP2020532987A5 (enExample) | 2021-10-21 |
Family
ID=64270934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513604A Pending JP2020532987A (ja) | 2017-09-08 | 2018-09-10 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| JP2024076622A Pending JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076622A Pending JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12385061B2 (enExample) |
| EP (1) | EP3679145A2 (enExample) |
| JP (2) | JP2020532987A (enExample) |
| CN (1) | CN111727256A (enExample) |
| AU (2) | AU2018329741B2 (enExample) |
| CA (1) | CA3072777A1 (enExample) |
| WO (1) | WO2019051424A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109689694B (zh) | 2016-05-19 | 2022-11-22 | 通用医疗公司 | 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台 |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| EP3679145A2 (en) | 2017-09-08 | 2020-07-15 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| SG11202111130SA (en) | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| AU2020264484A1 (en) | 2019-05-01 | 2021-11-04 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy |
| WO2020227166A1 (en) * | 2019-05-03 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| EP3753566A1 (en) * | 2019-06-21 | 2020-12-23 | Medizinische Hochschule Hannover | All-in one viral vector for car and therapeutic effector molecule |
| CN114245803A (zh) * | 2019-08-06 | 2022-03-25 | 儿童医疗中心有限公司 | 用于重构小神经胶质细胞的方法和组合物 |
| KR20220097875A (ko) | 2019-09-03 | 2022-07-08 | 마이얼로이드 테라퓨틱스, 인크. | 게놈 통합을 위한 방법 및 조성물 |
| CN114761418B (zh) * | 2019-12-02 | 2025-04-29 | 株式会社Lg化学 | Cho细胞衍生的蛋白分泌因子和包含它的表达载体 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US20230167464A1 (en) * | 2020-04-27 | 2023-06-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity |
| US20210363212A1 (en) * | 2020-05-21 | 2021-11-25 | Crispr Therapeutics Ag | Genetically engineered car t cells that secret interleukin-12 and therapeutic uses thereof |
| US20230322898A1 (en) * | 2020-07-31 | 2023-10-12 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising cell expressing chimeric receptor |
| WO2022226375A1 (en) * | 2021-04-23 | 2022-10-27 | Locanabio, Inc. | Tissue-targeted modified aav capsids and methods of use thereof |
| EP4082560B1 (en) * | 2021-04-27 | 2025-02-26 | Academia Sinica | Prap1 polypeptide for use in treating hypertriglyceridemia |
| US20240207405A1 (en) * | 2021-04-28 | 2024-06-27 | The General Hospital Corporation | Il2 tethered to its receptor il2rbeta and pore-forming proteins as a platform to enhance immune cell activity |
| EP4337268A4 (en) | 2021-05-11 | 2025-06-04 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| EP4373845A4 (en) * | 2021-07-23 | 2025-06-25 | The Children's Medical Center Corporation | Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use |
| CN114940974A (zh) * | 2021-09-28 | 2022-08-26 | 宁波熙宁检测技术有限公司 | 4-1bb报告基因293t稳转细胞株构建和应用 |
| US20250333758A1 (en) * | 2021-12-15 | 2025-10-30 | Genans Biotechnology Co., Ltd | Microglia having car and use thereof |
| CN115216492B (zh) * | 2022-06-29 | 2023-05-30 | 浙江欧赛思生物科技有限公司 | 一种小鼠原发神经胶质瘤模型的制备方法及其应用 |
| GB202219568D0 (en) * | 2022-12-22 | 2023-02-08 | Autolus Ltd | Chimeric antigen receptor |
| WO2025070635A1 (ja) * | 2023-09-27 | 2025-04-03 | 味の素株式会社 | 免疫細胞培養用培地 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
| US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
| US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
| US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| CA2067194C (en) | 1989-10-05 | 2003-03-18 | Glenn Kawasaki | Cell-free synthesis and isolation of novel genes and polypeptides |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU8081491A (en) | 1990-06-01 | 1991-12-31 | Cetus Corporation | Compositions and methods for identifying biologically active molecules |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| IE920562A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
| DE69814428T2 (de) | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
| JP2003135078A (ja) * | 2001-07-26 | 2003-05-13 | Japan Tobacco Inc | Ｃ型肝炎ウイルスｎｓ５ａタンパク質の変異体、およびその利用 |
| CA2551912A1 (en) * | 2003-12-29 | 2005-07-14 | Toudai Tlo, Ltd. | Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof |
| WO2006133398A2 (en) | 2005-06-08 | 2006-12-14 | Invitrogen Corporation | In vitro activated donor t-cells to promote transplant engraftment |
| AU2008271523B2 (en) | 2007-07-04 | 2015-09-10 | Max-Delbruck-Centrum Fur Molekulare Medizin | Hyperactive variants of the transposase protein of the transposon system Sleeping Beauty |
| CA2760446C (en) | 2009-04-30 | 2018-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| FR2952374B1 (fr) * | 2009-11-06 | 2012-11-16 | Univ Claude Bernard Lyon | Production de facteur ix recombinant dans une lignee cellulaire hepatocytaire humaine |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2761066B1 (en) | 2011-09-27 | 2018-12-05 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| CA2912172A1 (en) | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| KR102375998B1 (ko) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 항원 수용체 및 제조방법 |
| US10927384B2 (en) | 2014-04-09 | 2021-02-23 | Dna Twopointo Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| JP6782716B2 (ja) * | 2015-06-25 | 2020-11-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗体またはリガンドの結合および機能を明らかにするための細胞ベースアッセイ法 |
| GB2557123B (en) | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| GB201514875D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| RU2018133691A (ru) * | 2016-02-26 | 2020-03-26 | Посейда Терапьютикс, Инк. | Транспозонная система и способы ее применения |
| WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018213332A1 (en) | 2017-05-17 | 2018-11-22 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy |
| SG11202000145XA (en) | 2017-07-12 | 2020-02-27 | Refuge Biotechnologies Inc | Methods and systems for conditionally regulating gene expression |
| EP3679145A2 (en) | 2017-09-08 | 2020-07-15 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression |
| KR20210073520A (ko) | 2018-09-05 | 2021-06-21 | 포세이다 테라퓨틱스, 인크. | 동종이계 세포 조성물 및 이의 사용 방법 |
-
2018
- 2018-09-10 EP EP18800779.3A patent/EP3679145A2/en active Pending
- 2018-09-10 CN CN201880071587.1A patent/CN111727256A/zh active Pending
- 2018-09-10 WO PCT/US2018/050288 patent/WO2019051424A2/en not_active Ceased
- 2018-09-10 AU AU2018329741A patent/AU2018329741B2/en active Active
- 2018-09-10 JP JP2020513604A patent/JP2020532987A/ja active Pending
- 2018-09-10 US US16/640,788 patent/US12385061B2/en active Active
- 2018-09-10 CA CA3072777A patent/CA3072777A1/en active Pending
-
2024
- 2024-05-09 JP JP2024076622A patent/JP2024109657A/ja active Pending
-
2025
- 2025-05-21 AU AU2025203769A patent/AU2025203769A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532987A5 (enExample) | ||
| JP2024109657A5 (enExample) | ||
| Steeland et al. | A new venue of TNF targeting | |
| JP7227290B2 (ja) | キメラ抗原受容体、組成物及び方法 | |
| Schumacher et al. | ADAM17 activity and IL-6 trans-signaling in inflammation and cancer | |
| Xie et al. | CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia | |
| Roybal et al. | Engineering T cells with customized therapeutic response programs using synthetic notch receptors | |
| Rajagopalan et al. | Activation of NK cells by an endocytosed receptor for soluble HLA-G | |
| ES2965689T3 (es) | Receptores de células T anti-KRAS mutado | |
| Zuccolotto et al. | PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models | |
| Love et al. | Solution structure of CCL21 and identification of a putative CCR7 binding site | |
| JP2018519296A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| Vargas et al. | A TNFR2-specific TNF fusion protein with improved in vivo activity | |
| Yau et al. | Censoring of self-reactive b cells by follicular dendritic cell–displayed self-antigen | |
| Zhang et al. | Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity | |
| Hingtgen et al. | A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy | |
| US12331129B2 (en) | Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof | |
| Sabatini et al. | tTARGIT AAVs mediate the sensitive and flexible manipulation of intersectional neuronal populations in mice | |
| Okada et al. | Pore-forming spider venom peptides show cytotoxicity to hyperpolarized cancer cells expressing K+ channels: A lentiviral vector approach | |
| CN117500823A (zh) | 自身免疫中的嵌合蛋白 | |
| Prados et al. | CollagenVI-Cre mice: a new tool to target stromal cells in secondary lymphoid organs | |
| Xue et al. | An fc binding peptide-based facile and versatile build platform for multispecific antibodies | |
| Gamboa et al. | Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens | |
| US20210324041A1 (en) | Combination therapies |